Dilutional Coagulopathy in Patients Undergoing Elective Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00493272|
Recruitment Status : Completed
First Posted : June 28, 2007
Last Update Posted : December 2, 2015
The purpose of the present study is to perform a comprehensive description of haemostasis parameters before and after haemodilution with Hydroxyethyl starch (HES) following acute bleeding during elective surgery. Moreover the study aims to test the in vivo haemostatic potential of fibrinogen concentrate in dilutional coagulopathy caused by HES in a clinical, prospective, placebo-controlled randomised setup.
We hypothesise; a) A coagulopathy is induced following in vivo haemodilution; b) the coagulopathy is improved or partially improved by fibrinogen.
|Condition or disease||Intervention/treatment||Phase|
|Blood Coagulation Disorder||Drug: Fibrinogen||Phase 1 Phase 2|
Background Hydroxyethyl starch (HES) is a group of artificial colloid solutions widely used for plasma expansion and volume resuscitation. HES consist of branched chains of hydroxylated glucose molecules defined by average molecular weight, degree of hydroxyethylation, and C2/C6 ratio. Several clinical reports and in vitro experiments have documented an impaired coagulation system induced by haemodilution with HES and other colloid plasma expanders. The exact mechanisms responsible for HES induced coagulopahty are not fully understood although reduced levels of von Willebrand factor (vWF), acquired platelet dysfunction, reduced factor VIII levels, and dysfunctional fibrinogen polymerization seems to reflect an important aspect of the pathogenesis.
Experimental laboratory studies performed in our centre and verified by several other research groups have shown successful reversal of the colloid plasma expander induced coagulopathy by fibrinogen concentrate.10-13 So far, the present knowledge are based on laboratory experiments and animal studies. Hence, it appears desirable to perform a comprehensive description of haemostasis parameters following HES induced dilutional coagulopathy in an acute clinical bleeding situation.
Materials and Methods
Study design: Clinical, prospective, double-blind, randomised, place-controlled trial. Blood samples:
Primary end point:
Dynamic whole blood clot formation
Secondary end points:
A) Single coagulation factor activities B) Platelet function C) Whole blood clot stability. D) Thrombin generation
Serious surgical and traumatic bleedings are common and associated with a high mortality rate. The present study can significantly contribute to our overall understanding of the mechanisms involved in HES induced dilutional coagulopathy.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Fibrinogen vs Placebo for Improvement of Clot Strength|
|Study Start Date :||June 2007|
|Actual Primary Completion Date :||April 2008|
|Actual Study Completion Date :||April 2008|
Placebo Comparator: Placebo
Other Name: Active drug
Active Comparator: Fibrinogen
Other Name: Active drug
- Dynamic whole blood clot formation. [ Time Frame: 60 minutes ]
- A) Single coagulation factor activities B) Platelet function C) Whole blood clot stability. D) Thrombin generation. [ Time Frame: 60 minutes ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00493272
|Aarhus University Hospital, Department of Anaesthesiology|
|DK-8200 Aarhus N, Denmark|
|Principal Investigator:||Else Tønnesen, MD, Prof||Aarhus University Hospital, Department of Anaesthesiology|